Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transdermal Delivery vs Intralesional Injection of Compound Betamethasone in Keloids
NCT07835438Active, not recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Apr 2025
- Primary completion
- Jun 2026
- Countries
- 1
01
Overview
Randomised, open-label trial of compound betamethasone in keloid (2 arms), sponsored by First Hospital of China Medical University. Primary endpoint: Vancouver Scar Scale at 24 weeks. Started Apr 2025; status: active, not recruiting.
02
Drugs
compound betamethasone
03
Conditions
keloid
Beyond the preview
Go deeper on NCT07835438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07835438.